Skip to main content
OpenTrials
Completed

NCT Number: NCT04663061

Diabetes Data-Assisted Remission Trial (DDART)

The study team will study the efficacy of a high intensity medical weight loss intervention paired with a digital platform to create weight loss and induce remission of type 2 diabetes mellitus (T2DM) compared to a diabetes self-management education intervention. The digital platform provides the capability to tailor the treatment plan, provide automated support, and alert providers when a participant may need more support from the clinical team. If shown to be efficacious, this research could be highly impactful, causing us to rethink our approach to care for those with T2DM and shift the paradigm for millions of individuals in the United States. Furthermore, this approach will demonstrate the feasibility of helping people engage in metabolic treatment strategies in a way that is scalable leveraging digital and mobile solutions that extend the patient-provider relationship, shift care from episodic approaches to more of an on-going model that extends into the life of the patient, while also integrated within the healthcare system workflows.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wake Forest Univesity Health Sciences

Winston-Salem, North Carolina, 27157, United States

About this study

This project will determine if a data-assisted, high intensity medical weight loss intervention (HIWL) will lead to significant weight loss and diabetes remission in individuals with a Body Mass Index (BMI) 30-39.9 kg/m2 with T2DM of less than 6 years as compared to a diabetes self-management education intervention (DSME). Complete diabetes remission is considered to be achieved when the patient is not taking any anti-diabetes medication for at least 12 months, and the Glycated Hemoglobin (HbA1c) is < 5.7%. Partial remission is achieved when the patient is not taking any anti-diabetes medication and has an HbA1c of 5.7-6.4% for at least 12 months.Using a randomized controlled study design, we will randomly assign 90 participants to HIWL, HIWL + continuous glucose monitoring (CGM), or DSME. Participants assigned to HIWL will receive a high intensity behavioral weight loss intervention delivered using a digital patient engagement platform. Participants will be prescribed a low calorie dietary plan and a recommended physical activity program designed to produce 15-20% weight loss over 12 months. Those assigned to HIWL + CGM will receive the same intervention as HIWL; in addition we will provide them with CGM to use as part of their remote monitoring on a daily basis. Those assigned to DSME will participate in a comprehensive diabetes education program designed to provide education and skills for optimal diabetes management plus lifestyle modification counseling to produce 5% weight loss over the same timeframe. The primary outcome of weight loss will be assessed at 12 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Individuals with T2DM diagnosed within the past 6 years
  • Body Mass Index (BMI) of 30-39.9 kg/m2.
  • Participants must have an HbA1c between 6.5-11.9%.
  • Participants should be able to participate in all aspects of the recommended interventions, including being able to participate in exercise, make recommended dietary changes, and engage in individual and group counseling.

Exclusion criteria

  • Poorly controlled depression
  • Recent hospitalization for psychosis or bipolar disorder
  • Poorly controlled blood pressure (>159/99)
  • Prior surgical procedure for weight control or liposuction
  • Unable to make changes to their diet
  • Unable to exercise (walk for at least 6 minutes and perform simple strength and stretch exercise tests)
  • Use of weight loss medications in previous 3 months
  • Recent self-reported weight change (+/- 15lbs)
  • Current use of oral corticosteroids more than 5days/month
  • Cardiovascular disease event within the past 6 months
  • Severe pulmonary disease requiring supplemental oxygen
  • Renal failure (end stage renal disease)
  • History of non-skin cancer in the past 5 years
  • Major liver dysfunction within the last 2 years
  • Recently quit smoking less than 6 months prior
  • Inability to attend visits and adhere to study protocols
  • Pregnancy or currently lactating

Treatment and study plan

Medical Weight Loss

Behavioral

Participants will be prescribed intensive medical weight loss with the goal of achieving 15% weight loss from initial weight

Diabetes education

Behavioral

Participants will receive standard of care diabetes education

Continuous glucose monitoring

Behavioral

Participants will use CGM devices to track blood glucose levels in near real time

Primary outcomes

  1. Change in Body Weight

    Time frame: baseline through 12 months

    Change in weight from baseline

Secondary outcomes

  1. Change in Hemoglobin A1c

    Time frame: baseline through 12 months

    Change in hemoglobin A1c

  2. Number of Subjects in Diabetes Remission

    Time frame: 12 months

    Number of participants achieving A1c <6.5% and no anti-diabetes medications

  3. Continuous Glucose Monitoring (CGM) Time in Range

    Time frame: baseline and month 12

    Average time spent at an average glucose of 100 mg/dL or lower collected by FreeStyle Libre.

  4. Continuous Glucose Monitoring Time in Range--Post-meal Glucose

    Time frame: baseline through 12 months

    Average time spent at a post-meal glucose level of 110 mg/dL or lower collected by FreeStyle Libre.

  5. Continuous Glucose Monitor Time in Range--Fasting Glucose

    Time frame: baseline through 12 months

    Average time spent in normal fasting glucose between 72-85 mg/dL collected by FreeStyle Libre.

  6. Continuous Glucose Monitor - Episodes of Hypoglycemia

    Time frame: baseline and month 12

    Number of episodes hypoglycemia (<70 mg/dL) episodes collected by FreeStyle Libre.

  7. Continuous Glucose Monitor - Glucose Variability

    Time frame: baseline and month 12

    Coefficient of variance collected by FreeStyle Libre.

  8. Continuous Glucose Monitoring - Average Glucose

    Time frame: baseline and 12 months

    Average glucose (mg/dL) collected by FreeStyle Libre.

  9. Automated Self-Administered 24-hour (ASA24) Total Daily Energy Intake

    Time frame: baseline, 3 months, 6 months, and 12 months

    kilocalories averaged across 3 days

  10. ASA24 Macronutrient Composition of Diet

    Time frame: baseline, 3 months, 6 months, and 12 months

    %Carbohydrate/Fat/Protein; averaged across 3 days

  11. ASA24 Number of Eating Episodes Per Day

    Time frame: baseline, 3 months, 6 months, and 12 months

    averaged across 3 days

  12. ASA24 Healthy Eating Index (HEI)-2015 Score

    Time frame: baseline, 3 months, 6 months, and 12 months

    A validated summary measure of dietary quality, rated on a 100-point scale with a higher score denoting better diet quality

  13. Daily Step Counts

    Time frame: baseline, 3 months, 6 months, and 12 months

    Collected by pedometer over 7 days during each period. At the end of the 7th day, participants will record the final step count, and return the pedometer to the study team via a pre-stamped mail envelope.

  14. Change in Quality of Life

    Time frame: from baseline to month 12

    The EuroQol's EQ-5D-5L will be used to measure quality of life. This instrument takes responses to five questions on mobility, self-care, ability to perform usual activities, pain, and anxiety/depression to produce a validated quality score. Total score range is 5-25 with a lower score indicating a better quality of life.

  15. Change in Perceived Health Rating

    Time frame: from baseline to month 12

    The EuroQol's EQ-5D-5L visual analog scale will be used to measure participants perceived health. On a scale of 0-100 participants will rate their health. 0 means the worst health you can imagine. 100 means the best health you can imagine.

Other outcomes

  1. International Physical Activity Questionnaire (IPAC) Short Form: Walking Minutes

    Time frame: baseline, 3 months, 6 months, and 12 months

    A validated self-report measure of daily physical activity levels. Responses are given as minutes per day over the last week of walking for exercise. Outcome is average total minutes/week.

  2. International Physical Activity Questionnaire (IPAC) Short Form: Sitting Time

    Time frame: baseline, 3 months, 6 months, and 12 months

    A validated self-report measure of daily physical activity levels. Responses are given as minutes per day over the last week of sitting time. Outcome is average total minutes/week.

  3. International Physical Activity Questionnaire (IPAC) Short Form: Moderate-vigorous Physical Activity Minutes

    Time frame: baseline, 3 months, 6 months, and 12 months

    A validated self-report measure of daily physical activity levels. Responses are given as minutes per day over the last week of moderate and vigorous physical activity. Outcome is average total minutes/week.

Sponsors and collaborators

Lead sponsor

Wake Forest University Health Sciences

Other

Collaborators

  • UnitedHealth Group

Registry information

Official study title

Data-Assisted Approach for High Intensity Medical Weight Loss for Diabetes Remission

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Dec 10, 2020
Registry last updated
Apr 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.